Folks – as you know, I don’t pay lip service to the markets. The Dow dropped and recovered 1,000 points over the past week; and, if you’re looking for that kind of noise, there are plenty of sites out there discussing it. That said, let me paraphrase many investors I…
Today’s research and development (R&D) is tomorrow’s new product or process. The other day we (or more specifically, Phil Fisher) asked, “Does the management have a determination to continue to develop products or processes that will still further increase total sales potentials when the growth potentials of currently attractive product…
In Common Stocks and Uncommon Profits, Phil Fisher outlined fifteen points to look for when analyzing a company for purchase. When valuing a business, our job is to try and predict the future with a degree of accuracy and confidence. If it were as easy as plugging the financials into…
In late July, I posted an analysis of Amylin Pharmaceuticals (AMLN) that was not exactly a favorite of Michael’s. I figured that my response belonged in a post rather than in the comments because it was more of a “noise vs. news” debate, and Michael responded in turn with some…
Welcome to 2008 all. I am going to spend the next day responding to all of the comments from the past two weeks. Let’s get to the heart of the matter: What is going to happen in 2008? It is a question I have been hearing for the past three…
Interestingly enough, quick asked a question that was going to be the topic for today. When does the discounted cash flow model work? When does it not? Is this a method that can be used for all businesses at all times? The short answer is: The discounted cash flow method…
I like to think that I’m doing some good here on the blog. Your emails, comments, and return visits have led me to believe that. That said, I don’t think that I am a “guru” and that everyone else is wrong. My point on this site is simple: you can…
$6.22 billion. That’s what Wall Street is pricing Amylin Pharmaceuticals (AMLN) at these days. If you are a fan of Efficient Market Theory (Buffett isn’t), then you believe that the company is worth that much. You’d also have to believe that the company was fairly valued at $5 back in…